Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Patients With Recurrent or Metastatic, Advanced Solid Tumors

NCT06292858 is registered in ClinicalTrials.gov with Beijng Immunoah Pharma Tech Co., Ltd. as lead sponsor.

NCT NCT06292858
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06292858 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Preliminary Efficacy of IMB071703 Injection in Patients With Recurrent or Metastatic, Advanced Solid Tumors
Lead sponsor
Beijng Immunoah Pharma Tech Co., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
February 24, 2023
Completion date
August 31, 2025
Enrollment
93 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent or metastatic, advanced solid tumors